Last reviewed 2026-04-20 · How we verify

1.0mg Varenicline b.i.d. (1-0mg-varenicline-b-i-d)

Pfizer Inc. · preclinical active

1.0mg Varenicline b.i.d. (generic name: 1-0mg-varenicline-b-i-d) is a Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t drug developed by Pfizer Inc.. It is currently in preclinical development.

Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t

Varenicline 1.0mg twice daily is a nicotinic receptor partial agonist approved for smoking cessation. It reduces nicotine cravings and withdrawal symptoms while blocking the rewarding effects of cigarettes, making it one of the most effective pharmacologic aids for quitting smoking.

Likelihood of approval

8% vs 5% industry baseline

If approved by FDA: likely 2036–2040

Steps remaining: Phase 1 → Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Low

Why this estimate

Baseline preclinical → approval rate +5.0pp
Industry-wide preclinical drugs reach approval ~5% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
Pfizer Inc. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2036–2040	—
EMA	EU	2037–2041	+0.7 yr
MHRA	GB	2037–2041	+0.7 yr
Health Canada	CA	2037–2042	+0.9 yr
TGA	AU	2037–2042	+1.2 yr
PMDA	JP	2037–2042	+1.5 yr
NMPA	CN	2038–2043	+2.3 yr
MFDS	KR	2037–2042	+1.4 yr
CDSCO	IN	2037–2043	+1.8 yr
ANVISA	BR	2038–2043	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	1-0mg-varenicline-b-i-d
Sponsor	Pfizer Inc.
Drug class	Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t
Therapeutic area	Hematology
Phase	preclinical

Mechanism of action

Varenicline works by binding to specific receptors in your brain called nicotinic acetylcholine receptors—the same receptors that nicotine normally activates. As a partial agonist, varenicline acts like a weak version of nicotine, providing just enough stimulation to reduce the intense cravings and withdrawal discomfort that make quitting smoking so difficult. This approach is gentler than nicotine replacement therapy because it delivers a controlled, steady signal rather than mimicking the dramatic spikes from smoking. Simultaneously, varenicline blocks nicotine from attaching to these same receptors. If you do smoke while taking the medication, nicotine can't activate the reward pathways in your brain as strongly, making cigarettes far less satisfying. This dual action—reducing cravings while eliminating the pleasure from smoking—addresses both the physical addiction and the reinforcing cycle that keeps people smoking. At the standard dose of 1.0mg twice daily, varenicline reaches levels in your bloodstream that effectively occupy these brain receptors for most of the day. Over the typical 12-week treatment course, this allows your brain chemistry to gradually normalize while you break the behavioral habits of smoking, significantly improving your chances of successfully quitting.

Approved indications

No approved indications tracked.

Pipeline indications

Tobacco Dependence — preclinical

Common side effects

No common side effects on file.

Key clinical trials

Varenicline OTC Trial on Efficacy and Safety (Phase 4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

1.0mg Varenicline b.i.d. CI brief — competitive landscape report
1.0mg Varenicline b.i.d. updates RSS · CI watch RSS
Pfizer Inc. portfolio CI

Frequently asked questions about 1.0mg Varenicline b.i.d.

What is 1.0mg Varenicline b.i.d.?

1.0mg Varenicline b.i.d. (1-0mg-varenicline-b-i-d) is a Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t drug developed by Pfizer Inc..

How does 1.0mg Varenicline b.i.d. work?

Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t

Who makes 1.0mg Varenicline b.i.d.?

1.0mg Varenicline b.i.d. is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).

What is the generic name of 1.0mg Varenicline b.i.d.?

1-0mg-varenicline-b-i-d is the generic (nonproprietary) name of 1.0mg Varenicline b.i.d..

What drug class is 1.0mg Varenicline b.i.d. in?

1.0mg Varenicline b.i.d. belongs to the Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t class. See all Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t drugs at /class/varenicline-is-classified-as-a-selective-nicotine-receptor-partial-agonist-snrpa-that-works-both-t.

What development phase is 1.0mg Varenicline b.i.d. in?

1.0mg Varenicline b.i.d. is in preclinical.

Drug class: All Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t drugs
Manufacturer: Pfizer Inc. — full pipeline
Therapeutic area: All drugs in Hematology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing